Overview

Sayana® Press Self-injection Study in Malawi

Status:
Completed
Trial end date:
2017-08-30
Target enrollment:
Participant gender:
Summary
The feasibility of Sayana Press self-injection and the potential for this practice to increase contraceptive continuation has never been assessed in family planning programs in low-resource settings. The Malawi Ministry of Health (MOH) and the United States Agency for International Development (USAID) Malawi Mission requested the Advancing Partners and Communities (APC) project to assess self-injection of Sayana Press to inform their decision-making for procurement of Sayana Press and distribution through the health system in Malawi.
Phase:
N/A
Details
Lead Sponsor:
FHI 360
Treatments:
Medroxyprogesterone
Medroxyprogesterone Acetate